▶Febuxostatis predicted to increase the exposure to
azathioprine. Avoid.rTheoretical
▶Live vaccinesare predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
azathioprine(high-dose). Public Health England advises avoid
(refer to Green Book).rTheoretical
Azelastine→see antihistamines, non-sedating
Azilsartan→see angiotensin-II receptor antagonists
Azithromycin→see macrolides
Bacillus Calmette-Guérin vaccine→see live vaccines
Bacitracin→seeTABLE 2p. 847 (nephrotoxicity)
Baclofen→seeTABLE 8p. 848 (hypotension),TABLE 11p. 849 (CNS
depressant effects),TABLE 10p. 849 (antimuscarinics)
▶Baclofenis predicted to increase the risk of side-effects when
given withlevodopa.rAnecdotal→Also seeTABLE 8p. 848
Balsalazide→seeTABLE 15p. 850 (myelosuppression)
▶Balsalazideis predicted to decrease the concentration of
digoxin.oTheoretical
Bambuterol→see beta 2 agonists
Baricitinib
▶Leflunomidepotentially increases the exposure tobaricitinib.
oTheoretical
▶Live vaccinesare predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
baricitinib. Avoid.rTheoretical
▶Teriflunomidepotentially increases the exposure tobaricitinib.
oTheoretical
Basiliximab→see monoclonal antibodies
Bazedoxifene
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)are predicted to decrease the exposure
tobazedoxifene.oTheoretical
▶Rifampicinis predicted to decrease the exposure to
bazedoxifene.oTheoretical
Beclometasone→see corticosteroids
Bedaquiline→seeTABLE 9p. 849 (QT-interval prolongation)
▶Antiarrhythmics(dronedarone)are predicted to increase the
exposure tobedaquiline. Avoid prolonged use.n
Theoretical→Also seeTABLE 9p. 849
▶Antiepileptics(carbamazepine, fosphenytoin, phenobarbital,
phenytoin, primidone)decrease the exposure tobedaquiline.
Avoid.rStudy
▶Antifungals, azoles(fluconazole, isavuconazole, posaconazole)
are predicted to increase the exposure tobedaquiline. Avoid
prolonged use.nTheoretical→Also seeTABLE 9p. 849
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure tobedaquiline. Avoid
prolonged use.nStudy→Also seeTABLE 9p. 849
▶Aprepitantis predicted to increase the exposure to
bedaquiline. Avoid prolonged use.nTheoretical
▶Bosentanis predicted to decrease the exposure tobedaquiline.
Avoid.rStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tobedaquiline. Avoid prolonged use.
nTheoretical
▶Clofaziminepotentially increases the risk of QT-prolongation
when given withbedaquiline.rStudy
▶Cobicistatis predicted to increase the exposure tobedaquiline.
Avoid prolonged use.nStudy
▶Crizotinibis predicted to increase the exposure tobedaquiline.
Avoid prolonged use.nTheoretical→Also seeTABLE 9p. 849
▶Efavirenzis predicted to decrease the exposure tobedaquiline.
Avoid.rStudy→Also seeTABLE 9p. 849
▶Enzalutamidedecreases the exposure tobedaquiline. Avoid.
rStudy
▶Etravirineis predicted to decrease the exposure tobedaquiline.
Avoid.rTheoretical
▶HIV-protease inhibitorsare predicted to increase the exposure
tobedaquiline. Avoid prolonged use.nStudy→Also see
TABLE 9p. 849
▶Idelalisibis predicted to increase the exposure tobedaquiline.
Avoid prolonged use.nStudy
▶Imatinibis predicted to increase the exposure tobedaquiline.
Avoid prolonged use.nTheoretical
▶Macrolides(clarithromycin)are predicted to increase the
exposure tobedaquiline. Avoid prolonged use.nStudy→
Also seeTABLE 9p. 849
▶Macrolides(erythromycin)are predicted to increase the
exposure tobedaquiline. Avoid prolonged use.n
Theoretical→Also seeTABLE 9p. 849
▶Mitotanedecreases the exposure tobedaquiline. Avoid.r
Study
▶Netupitantis predicted to increase the exposure to
bedaquiline. Avoid prolonged use.nTheoretical
▶Nevirapineis predicted to decrease the exposure to
bedaquiline. Avoid.rStudy
▶Nilotinibis predicted to increase the exposure tobedaquiline.
Avoid prolonged use.nTheoretical→Also seeTABLE 9p. 849
▶Rifampicindecreases the exposure tobedaquiline. Avoid.
rStudy
▶St John’sWortis predicted to decrease the exposure to
bedaquiline. Avoid.rStudy
Bee venom extract
GENERAL INFORMATIONDesensitising vaccines should be
avoided in patients taking beta-blockers (adrenaline might be
ineffective in case of a hypersensitivity reaction) or ACE
inhibitors (risk of severe anaphylactoid reactions).Belatacept
▶Live vaccinesare predicted to increase the risk of generalised
infection (possibly life-threatening) when given with
belatacept. Public Health England advises avoid (refer to
Green Book).rTheoretical
Belimumab→see monoclonal antibodies
Bendamustine→see alkylating agents
Bendroflumethiazide→see thiazide diuretics
Benperidol→seeTABLE 8p. 848 (hypotension),TABLE 11p. 849 (CNS
depressant effects)
▶Benperidolis predicted to decrease the effects ofdopamine
receptor agonists. Avoid.oTheoretical→Also seeTABLE 8
p. 848
▶Benperidolis predicted to decrease the effects ofguanethidine.
oTheoretical→Also seeTABLE 8p. 848
▶Benperidolis predicted to decrease the effects oflevodopa.
rStudy→Also seeTABLE 8p. 848
Benralizumab→see monoclonal antibodies
Benzydamine→see NSAIDs
Benzylpenicillin→see penicillins
Beta blockers, non-selective→seeTABLE 6p. 848 (bradycardia),
TABLE 8p. 848 (hypotension),TABLE 9p. 849 (QT-interval prolongation)
carvedilol.labetalol.levobunolol.nadolol.oxprenolol.pindolol.
propranolol.sotalol.timolol..ROUTE-SPECIFIC INFORMATIONSince systemic absorption can
follow topical application oflevobunololandtimolol,the
possibility of interactions should be borne in mind.
▶Beta blockers, non-selectiveare predicted to increase the risk
of bronchospasm when given withaminophylline. Avoid.
rTheoretical
▶Antiarrhythmics(amiodarone, disopyramide, dronedarone,
flecainide, lidocaine)are predicted to increase the risk of
cardiovascular side-effects when given withbeta blockers,
non-selective. Use with caution or avoid.rStudy→Also see
TABLE 6p. 848→Also seeTABLE 9p. 849
▶Antiarrhythmics(propafenone)increase the risk of
cardiovascular side-effects when given withpropranolol. Use
with caution or avoid.rStudy
▶Antiarrhythmics(propafenone)are predicted to increase the
exposure totimololandtimololis predicted to increase the risk
of cardiodepression when given withantiarrhythmics
(propafenone).rAnecdotal
▶Antiarrhythmics(propafenone)are predicted to increase the risk
of cardiovascular side-effects when given withbeta blockers,
non-selective(labetalol, levobunolol, nadolol, oxprenolol,
pindolol, sotalol). Use with caution or avoid.rStudy
▶Anticholinesterases, centrally actingare predicted to increase
the risk of bradycardia when given withbeta blockers, non-
selective.oAnecdotal→Also seeTABLE 6p. 848BNFC 2018 – 2019 Azathioprine—Beta blockers, non-selective 883
Interactions|Appendix 1A1